Development and validation of a clinical score for identifying patients with high risk of latent autoimmune adult diabetes (LADA): The LADA primary care-protocol study.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Diabetes Mellitus, Type 1*/diagnosis ; Diabetes Mellitus, Type 2*/diagnosis ; Autoimmune Diseases*/diagnosis ; Glucose Intolerance* ; Latent Autoimmune Diabetes in Adults*/diagnosis; Humans ; Adult ; Cross-Sectional Studies ; Autoantibodies ; Primary Health Care ; Observational Studies as Topic

Background: Latent autoimmune diabetes in adults (LADA) is a type of diabetes mellitus showing overlapping characteristics between type 1 Diabetes Mellitus and type 2 Diabetes Mellitus (T2DM), and autoimmunity against insulin-producing pancreatic cells. For its diagnosis, at least one type of anti-pancreatic islet antibody (GADAb is the most common) is required. Many authors recommend performing this measure in all newly diagnosed patients with DM, but it is not possible in Primary Health Care (PHC) due to its high cost. Currently, a relevant proportion of patients diagnosed as T2DM could be LADA. Confusing LADA with T2DM has clinical and safety implications, given its different therapeutic approach. The main objective of the study is to develop and validate a clinical score for identifying adult patients with DM at high risk of LADA in PHC.
Methods: This is an observational, descriptive, cross-sectional study carried out in Primary Care Health Centers with a centralized laboratory. All people over 30 years of age diagnosed with diabetes within a minimum of 6 months and a maximum of 4 years before the start of the study will be recruited. Individuals will be recruited by consecutive sampling. The study variables will be obtained through clinical interviews, physical examinations, and electronic medical records. The following variables will be recorded: those related to Diabetes Mellitus, sociodemographic, anthropometric, lifestyle habits, laboratory parameters, presence of comorbidities, additional treatments, personal or family autoimmune disorders, self-perceived health status, Fourlanos criteria, and LADA diagnosis (as main variable) according to current criteria.
Discussion: The study will provide an effective method for identifying patients at increased risk of LADA and, therefore, candidates for antibody testing. However, a slight participation bias is to be expected. Differences between participants and non-participants will be studied to quantify this potential bias.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Vich-Pérez et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Aten Primaria. 2007 Mar;39(3):133-7. (PMID: 17386205)
Pharmacotherapy. 2017 Feb;37(2):187-194. (PMID: 27931088)
Diabet Med. 2011 Mar;28(3):319-24. (PMID: 21309840)
Eur J Endocrinol. 2011 Feb;164(2):239-45. (PMID: 21088056)
Diabetologia. 2005 Nov;48(11):2206-12. (PMID: 16193284)
Endocrinology. 2010 Jul;151(7):3049-60. (PMID: 20444936)
Diabetes Care. 2014 Jun;37(6):1643-9. (PMID: 24722498)
J Clin Endocrinol Metab. 2021 Mar 25;106(4):e1529-e1541. (PMID: 33475138)
Diabetes Care. 2007 Apr;30(4):932-8. (PMID: 17392553)
J Nutr. 2011 Jun;141(6):1140-5. (PMID: 21508208)
Diabetes Care. 2014;37(1):e11-2. (PMID: 24356601)
Int J Environ Res Public Health. 2015 Jan 23;12(2):1237-52. (PMID: 25625405)
Diabetes Metab J. 2018 Dec;42(6):451-464. (PMID: 30565440)
Diabetologia. 2011 Aug;54(8):1985-91. (PMID: 21547496)
Diabetes Metab Res Rev. 2017 Jul;33(5):. (PMID: 28198081)
Stat Med. 1997 May 15;16(9):965-80. (PMID: 9160492)
Diabetes. 2013 Feb;62(2):543-50. (PMID: 23086039)
Heart. 2011 Mar;97(6):491-9. (PMID: 21097820)
PLoS One. 2015 Aug 07;10(8):e0131837. (PMID: 26252955)
Diabetes Care. 2013 Apr;36(4):908-13. (PMID: 23248199)
Diabetes. 2000 Jun;49(6):918-25. (PMID: 10866043)
Diabetes Care. 2009 Dec;32(12):2251-7. (PMID: 19808924)
Diabetes Care. 2004 Mar;27(3):727-33. (PMID: 14988293)
J Clin Endocrinol Metab. 2014 May;99(5):E876-80. (PMID: 24432999)
Endocrinol Metab (Seoul). 2018 Jun;33(2):147-159. (PMID: 29947172)
Diabetes. 2004 Dec;53(12):3193-200. (PMID: 15561950)
Diabetes. 1999 Jan;48(1):150-7. (PMID: 9892237)
J Clin Endocrinol Metab. 2009 Jan;94(1):81-8. (PMID: 18957505)
Lancet Diabetes Endocrinol. 2016 Mar;4(3):221-232. (PMID: 26656289)
PLoS One. 2016 Jul 21;11(7):e0158489. (PMID: 27441722)
Diabetes Res Clin Pract. 2002 Jun;56(3):213-20. (PMID: 11947969)
BMC Med Res Methodol. 2011 Oct 28;11:146. (PMID: 22035202)
Clin Ther. 2016 Dec;38(12):2654-2664.e1. (PMID: 28003053)
Diabetes Care. 2001 Aug;24(8):1460-7. (PMID: 11473087)
J Clin Endocrinol Metab. 2008 Jun;93(6):2115-21. (PMID: 18397986)
Endocrinol Diabetes Nutr. 2017 Jan;64(1):34-39. (PMID: 28440768)
Diabetes Care. 2006 May;29(5):970-5. (PMID: 16644622)
Eur J Endocrinol. 2010 Oct;163(4):541-9. (PMID: 20603341)
Aten Primaria. 2015 Mar;47(3):175-83. (PMID: 25443767)
J Diabetes Res. 2017;2017:9016148. (PMID: 28573146)
Endocr Pract. 2016 Jun;22(6):753-62. (PMID: 27082665)
Stat Med. 2004 Aug 30;23(16):2567-86. (PMID: 15287085)
Lancet. 1997 Nov 1;350(9087):1288-93. (PMID: 9357409)

0 (Autoantibodies)

Date Created: 20230209 Date Completed: 20230213 Latest Revision: 20230407

20231215

PMC9910627

10.1371/journal.pone.0281657

36758065